Amgen Inc. (NASDAQ:AMGN) had its target price lifted by Argus from $180.00 to $195.00 in a research note published on Thursday morning. Argus currently has a buy rating on the medical research company’s stock.

Several other equities research analysts have also recently commented on the company. Jefferies Group LLC cut Amgen from a buy rating to a hold rating and decreased their target price for the stock from $194.00 to $180.00 in a research note on Wednesday, April 5th. Credit Suisse Group reaffirmed a hold rating and set a $178.00 target price on shares of Amgen in a research note on Tuesday, April 4th. Cowen and Company reaffirmed an outperform rating and set a $209.00 target price on shares of Amgen in a research note on Wednesday, April 19th. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and set a $189.00 target price on shares of Amgen in a research note on Friday, June 30th. Finally, BidaskClub raised Amgen from a buy rating to a strong-buy rating in a research note on Friday, June 23rd. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the stock. Amgen has a consensus rating of Buy and an average target price of $186.64.

Shares of Amgen (NASDAQ:AMGN) traded up 0.95% during mid-day trading on Thursday, reaching $176.19. The company had a trading volume of 827,962 shares. The company has a market cap of $128.56 billion, a price-to-earnings ratio of 16.05 and a beta of 1.35. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21. The firm’s 50-day moving average price is $172.48 and its 200 day moving average price is $166.30.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same period last year, the company earned $2.84 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. Equities analysts expect that Amgen will post $12.57 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) PT Raised to $195.00” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/amgen-inc-amgn-pt-raised-to-195-00/1464008.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.64%. Amgen’s dividend payout ratio (DPR) is currently 41.93%.

In related news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of AMGN. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the period. Capital Advisors Ltd. LLC raised its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after buying an additional 7 shares during the period. Investment Partners Ltd. OH ADV raised its stake in shares of Amgen by 0.5% in the second quarter. Investment Partners Ltd. OH ADV now owns 2,192 shares of the medical research company’s stock worth $377,000 after buying an additional 11 shares during the period. Conservest Capital Advisors Inc. raised its stake in shares of Amgen by 0.4% in the second quarter. Conservest Capital Advisors Inc. now owns 3,130 shares of the medical research company’s stock worth $539,000 after buying an additional 13 shares during the period. Finally, Arvest Bank Trust Division raised its stake in shares of Amgen by 0.9% in the second quarter. Arvest Bank Trust Division now owns 1,508 shares of the medical research company’s stock worth $260,000 after buying an additional 13 shares during the period. Institutional investors and hedge funds own 78.82% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.